Sleep medicine · 2025
Positive airway pressure therapy and cardiovascular events in obstructive sleep apnoea: an observational clinical cohort study.
СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mazzotti Diego R, Chen Aiyu, An Jaejin, Chung Joanie, Arguelles Jessica, Keenan Brendan T, Maislin Greg, Saconi Bruno, Watach Alexa J, Glick Henry, Kuna Samuel T, Pack Allan I, Sawyer Amy M, Hwang Dennis, Shi Jiaxiao
Аннотация
AIMS: Studies support the short-term benefit of continuous positive airway pressure (CPAP) therapy on cardiometabolic risk in adults with obstructive sleep apnoea (OSA). Evidence is limited on the benefits of CPAP for preventing acute major adverse cardiovascular events (MACE). This study aimed to assess the association between CPAP use and incidence of MACE in a longitudinal clinical cohort of adults with OSA at a large U.S. healthcare system.
METHODS: Adults with OSA (apnoea-hypopnoea index [AHI]≥5) were identified from Kaiser Permanente Southern California between 2018 and 2020 (N = 34,782). MACE was defined as first occurrence of myocardial infarction, stroke, unstable angina, heart failure or cardiovascular death, using validated electronic health record algorithms. CPAP use (h/night) was based on daily telemonitoring data. Inverse probability of treatment weighted Cox proportional hazards models stratified by OSA severity (mild [5≤AHI<15]), moderate-severe [AHI ≥15]), were used to assess associations between CPAP use and MACE.
RESULTS: Among individuals with moderate-severe OSA, those using CPAP <4 h/night (HR [95 % CI] = 0.53 [0.35-0.82]; p = 0.004) or ≥4 h/night (HR [95 % CI] = 0.46 [0.27-0.77]; p = 0.004) had lower MACE incidence compared to those not using CPAP. Increased CPAP use (in hours) was associated with lower MACE incidence in moderate-severe OSA (HR [95 % CI] = 0.90 [0.82-0.98]; p = 0.021). In individuals with mild OSA, CPAP use was not associated with lower MACE incidence.
CONCLUSION: CPAP use was associated with lower MACE incidence in adults with moderate-severe OSA. Treatment of moderate-severe OSA may have a positive impact on prevention of MACE.
METHODS: Adults with OSA (apnoea-hypopnoea index [AHI]≥5) were identified from Kaiser Permanente Southern California between 2018 and 2020 (N = 34,782). MACE was defined as first occurrence of myocardial infarction, stroke, unstable angina, heart failure or cardiovascular death, using validated electronic health record algorithms. CPAP use (h/night) was based on daily telemonitoring data. Inverse probability of treatment weighted Cox proportional hazards models stratified by OSA severity (mild [5≤AHI<15]), moderate-severe [AHI ≥15]), were used to assess associations between CPAP use and MACE.
RESULTS: Among individuals with moderate-severe OSA, those using CPAP <4 h/night (HR [95 % CI] = 0.53 [0.35-0.82]; p = 0.004) or ≥4 h/night (HR [95 % CI] = 0.46 [0.27-0.77]; p = 0.004) had lower MACE incidence compared to those not using CPAP. Increased CPAP use (in hours) was associated with lower MACE incidence in moderate-severe OSA (HR [95 % CI] = 0.90 [0.82-0.98]; p = 0.021). In individuals with mild OSA, CPAP use was not associated with lower MACE incidence.
CONCLUSION: CPAP use was associated with lower MACE incidence in adults with moderate-severe OSA. Treatment of moderate-severe OSA may have a positive impact on prevention of MACE.